Clozapine-induced agranulocytosis and its genetic determinants

Pharmacogenomics

Volumn 9, Issue 8, 2008, Pages 1101-1111

  Opgen Rhein, Carolin ^a   Dettling, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adverse drug reactions; Agranulocytosis; Antipsychotics; Clozapine; HLA system; Myeloperoxidase; Pathomechanisms

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DRUG METABOLIZING ENZYME; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; LITHIUM; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELOPEROXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

AGRANULOCYTOSIS; BONE MARROW DISEASE; DISEASE COURSE; DRUG FATALITY; DRUG WITHDRAWAL; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; INFECTION; LEUKOCYTOSIS; NEUTROPENIA; REVIEW; SCHIZOPHRENIA;

AGRANULOCYTOSIS; ANIMALS; CLOZAPINE; GENETIC VARIATION; HUMANS; LINKAGE (GENETICS); PSYCHOTIC DISORDERS;

EID: 50149096834     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.8.1101     Document Type: Review

References (73)

1. Ibanez L, Vidal X, Ballarin E, Laporte JR: Population-based drug-induced agranulocytosis. Arch. Intern. Med. 165, 869-874 (2005).
2. Andersohn F, Konzen C, Garbe E: Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med. 146, 657-665 (2007).
3. Alvir JM, Liebeman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329, 162-167 (1993).
4. Hippius H, Kanig K: Die agranulocytose unter neuro-psychiatrischer phenothiazintherapie. Ärztliche Wochenschrift. 13, 501-507 (1958).
5. Stübner S, Grohmann R, Engel R et al.: Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 37(Suppl 1), S70-S78 (2004).
6. Johnsen H, Husbekk A, Skjelbakken T: Severe antibody-mediated agranulocytosis. Int. J. Lab. Hematol. 30, 71-74 (2008).
7. Bux J, Ernst-Schlegel M, Rothe B, Panzer C: Neutropenia and anaemia due to carbimazole-dependent antibodies. Br. J. Haematol. 109, 243-247 (2000).
8. Lorenz M, Evering WE, Provencher A et al.: Atypical antipsychotic-induced neutropenia in dogs. Toxicol. Appl. Pharmacol. 155, 227-236 (1999).
9. Hippius H: The history of clozapine. Psychopharmacology (Berl.) 99 (Suppl.), S3-S5 (1989).
10. Idänpään-Heikkila J, Alhava E, Olkinura M et al.: Agranulocytosis during treatment with chlozapine. Eur. J. Clin. Pharmacol. 11, 193-198 (1977).
11. Citrome L, Bilder RM, Volavka J: Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J. Psychiatr. Pract. 8, 205-215 (2002).
12. Uetrecht JP: The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24, 299-366 (1992).
13. Uetrecht JP: Reactive metabolites and agranulocytosis. Eur J. Haematol. 60(Suppi.), 83-88 (1996).
14. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci, 22, 298-305 (2001).
15. Park BK, Pirmohamed M, Kitteringham NR: Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34, 377-395 (1992).
16. Price KO: Ethnicity and clozapine-induced agranulocytosis. Clin. Pharm. 10, 743-744 (1991).
17. Horacek J, Libier J, Höschl C, Borzova K, Hendrychova I: Clozapine-induced concordant agranulocytosis in monozygotic twins. Int. J. Psychiatry Clin. Pract. 5, 71-73 (2001).
18. Ghodke Y, Joshi K, Chopra A, Patwardhan B: HLA and disease. Eur. J. Epidemiol. 20, 475-488 (2005).
19. Wright P, Nimgaonkar VL, Donaldson PT, Murray RM: Schizophrenia and HLA: a review. Schizophr. Res. 471, 1-12 (2001).
20. Lieberman JA, Yunis J, Egea E, Canoso RT. Kane M, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 47, 945-948 (1990).
21. Yunis JJ, Lieberman J, Yunis EJ: Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf. 7 (Suppi. 1), 7-9 (1992).
22. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ: HLA associations in clozapine-induced agranulocytosis. Blood 86, 1177-1183 (1995).
23. Valevski A, Klein T, Gazit E et al.: HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. 25, 11-13 (1998).
24. Amar A, Segman RH. Shtrussberg S et al.: An association between clozapine-Induced agranulocytosis in schizophrenics and HLA-DQBI*0201. Int. J. Neurapsychopharmacol, 1, 41-44 (1998).
25. Dettling M. Schaub RT, Mueller-Oerlinghausen B, Roots I, Cacscorbi I: Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 11, 135-141 (2001).
26. Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B: Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish caucasian sample. Arch. Gen. Psychiatry 58, 93-94 (2001).
27. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R: Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenonmics J. 7, 325-332 (2007).
28. Miretti MM, Walsh EC, Ke X et al.: A high-resolution linkage-disequilibrium map of the human major histocompatibility complex. Am. J. Hum. Genet. 764, 634-646 (2005).
29. Williams F, Meenagh A, Darke C et al.: Analysis of the distribution of HLA-B alleles in populations from five continents. Hum. Immunol. 62, 645-650 (2001).
30. Cao K, Houenbach J, Shi X: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution pattern in these populations. Hum. Immunol. 62, 1009-1030 (2001).
31. Fan QR, Mosyak L, Winter CC et al.: Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Nature 389, 96-100 (1997).
32. Lahdelma L, Ahokas A, Andersson LC: Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J. Clin. Psychopharmacol. 21, 4-7 (2001).
33. Barretto A, Gonzales JM, Kabingu E, Asea A, Fiorentino A: Stress-induced release of HSC70 from human tumors. Cell. Mol. Immunol. 222, 97-104 (2003).
34. Schwab SG, Hallmayer J, Frimann J et al.: Investigation of linkage and association/linkage disequilibrium of HLA A-, DQA1-, DQB1-, and DRB1-alleles in 69 sib-pair- and 89 trio-families with schizophrenia. Am. J. Med. Genet. 114, 315-320 (2002).
35. Corzo D, Yunis JJ, Salazar M: The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86, 3835-3840 (1995).
36. Corzo D, Yunis JJ, Yunis EJ, Howard A, Lieberman JA: HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 55(Suppl. B), 149-152 (1994).
37. Hajeer AH, Hutchinson IV: TNF-α gene polymorphism: clinical and biological implications. Microsc. Res. Tech. 50, 216-228 (2000).
38. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M: Association between -G308A tumor necrosis factor α gene polymorphism and schizophrenia. Mol. Psychiatry 6, 79-82 (2001).
39. Watanabe Y, Muratake T, Keneko N, Fukui N, Nara Y, Someya T: No association between the tumor necrosis factor-α gene promoter polymorphisms and schizophrenia in a Japanese population. Psychiatry Res. 153, 1-6 (2007).
40. Pollmacher T, Hinze-Selch D, Mullington J: Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16, 403-409 (1996).
41. Turbay D, Lieberman J, Alper CA et al.: Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 89, 4167-4174 (1997).
42. Wang W, Le WD, Pan T, Stringer JL, Jaiswal AK: Association of NRH: quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J. Gerontol. A Biol. Sci. Med. Sci. 63, 127-134 (2008).
43. Harada S, Fujii C, Hayashi A, Okoshi N: An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem. Biophys. Res. Commun. 288, 887-892 (2001).
44. IIda A, Semine A, Saito S et al.: Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. J. Hum. Genet. 46, 225-240 (2001).
45. Harada S, Tachikawa H. Kawanishi Y: A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiatr. Genet. 13, 205-209 (2003).
46. Ohgake S, Hashimoto K, Shimizu E et al.: Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict. Biol. 10, 145-148 (2005).
47. Ostrousky O, Meged S, Loewenthal R: NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 62, 483-491 (2003).
48. van der Pol, van de Winkel JGJ: IgG receptor polymorphisms: risk factors for disease. Immunogenetics 48, 222-232 (1998).
49. Fanger NA, Voigtlaender D, Liu C et al.: Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc γ RI (CD64) expressed on human blood dendritic cells. J. Immunol. 158, 3090-1098 (1997).
50. Nimmerjahn F, Ravetch JV: Fc γ receptors as regulators of immune responses. Nat. Rev. Immunol. 1, 34-47 (2008).
51. Carlsson LE, Santoso S, Baurichter G et al.: Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood 92, 1526-1531 (1998).
52. Mosyagin I, Cascorbi I, Schaub R, Krüger T, Dettling M: Drug-induced agranulocytosis: impact of different Fcγ receptor polymorphisms? Clin. Pychopharmacol. 25, 435-440 (2005).
53. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y: NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet. Med. 7, 463-478 (2005).
54. Foster CB, Lehrnbecher T, Mol F et al.: Host defence molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J. Clin. Invest. 102, 2146-2155 (1998).
55. Chevrier I, Stucker AM, Houllier S et al.: Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics 13, 729-739 (2003).
56. Schabath MB, Spitz MR, Hong WK et al.: A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 37, 35-40 (2002).
57. le Marchand L, Seifried A, Lum A, Wilkens LR: Association of the myeloperoxidase -463GA polymorphism with lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 9, 181-184 (2000).
58. Ago T, Nunoi H, Ito T, Sumimoto H: Mechanism for phosphorylation-induced activation of the phagocyte NADPH oxidase protein p47 (phox). Triple replacement of serines 303, 304, and 328 with aspartates disrupts the sh3 domain-mediated intramolecular interaction in p47 (phox), thereby activating the oxidase. J. Biol. Chem. 274, 33644-33653 (1999)
59. Batot G, Martel C, Capdeville N, Wientjes F, Morel F: Characterization of neutrophil NADPH oxidase activity reconstituted in a cell-free assay using specific monoclonal antibodies raised against cytochrome b558. Eur. J. Biochem. 234, 208-215 (1995).
60. Babior BM: NADPH oxidase: an update. Blood 93, 1464-1476 (1999).
61. Roos D, de Boer M, Kuribayashi F et al.: Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 87, 1663-1681 (1996).
62. Casimir CM, Bu-Ghanim HN, Rodaway ARF, Bentley DL, Rowe P, Segal AW: Autosomal recessive granulomatous disease caused by deletion at a dinucleotide repeat. Proc. Natl Acad. Sci. USA 88, 2753-2757 (1991).
63. Uetrecht JP: Current trends in drug-induced autoimmunity. Toxicology 119, 37-43 (1997).
64. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I: Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J. Clin. Psychopharmacol. 24, 613-617 (2004).
65. Dettling M, Sachse C, Müller-Oerlinghausen B et al.: Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 33, 218-220 (2000).
66. Chandrasekaran PK: Agranulocytosis monitoring with clozapine patients: to follow guidelines or to attempt therapeutic controversies? Singapore Med. J. 49, 96-99 (2008).
67. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J: Reducing clozapine-related morbidity and mortality: five years of experience with the Clozaril National Registry. J. Clin. Psychiatry 59(Suppl. 3). 3-7 (1998).
68. Chin-Yee I, Bezchlibnyk-Butier & Wong L: Use of cytokines in clozapine-induced agranulocytosis. Can. J. Psychiatry 41, 280-284 (1996).
69. Mathewson KA, Lindenmayer JP: Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia. J. Clin. Psychopharmacol. 27, 714-715 (2007).
70. Esposito D, Rouilion F, Limosin F: Continuing clozapine treatment despite neutropenia. Eur. J. Clin. Pharmacol. 60, 759-764 (2005).
71. The International SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
72. Tamam L, Kulan E, Ozpoyraz N: Late onset neutropenia during clozapine treatment. Psychiatry Clin. Neurosci. 55, 547-548 (2001).
73. Dunk LR, Annan LJ, Andrews CD: Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br. J. Psychiatry 188, 255-263 (2006).